Maxim Group downgraded Inovio Pharma from Buy to Hold
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/9/2025 | $5.00 | Overweight | Piper Sandler |
| 5/14/2024 | $20.00 | Overweight | Stephens |
| 1/25/2024 | $4.00 | Perform → Outperform | Oppenheimer |
| 11/9/2022 | Buy → Hold | Maxim Group | |
| 11/1/2022 | $2.00 | Neutral → Underperform | BofA Securities |
| 7/19/2022 | $5.00 → $4.00 | Sector Perform | RBC Capital Mkts |
| 5/11/2022 | Outperform → Perform | Oppenheimer | |
| 3/2/2022 | $6.00 → $5.00 | Sector Perform | RBC Capital |
Piper Sandler initiated coverage of Inovio Pharma with a rating of Overweight and set a new price target of $5.00
Stephens initiated coverage of Inovio Pharma with a rating of Overweight and set a new price target of $20.00
Oppenheimer upgraded Inovio Pharma from Perform to Outperform and set a new price target of $4.00
8-K - INOVIO PHARMACEUTICALS, INC. (0001055726) (Filer)
SCHEDULE 13G/A - INOVIO PHARMACEUTICALS, INC. (0001055726) (Subject)
8-K - INOVIO PHARMACEUTICALS, INC. (0001055726) (Filer)
4 - INOVIO PHARMACEUTICALS, INC. (0001055726) (Issuer)
4 - INOVIO PHARMACEUTICALS, INC. (0001055726) (Issuer)
4 - INOVIO PHARMACEUTICALS, INC. (0001055726) (Issuer)
PLYMOUTH MEETING, Pa., May 28, 2026 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer and infectious diseases, today announced that it will participate in the following scientific and investor conferences: Jefferies Global Healthcare Conference (New York) Date: Thursday, June 4 Time: 8:45 AM ET Format: Fireside Chat Webcast: https://event.summitcast.com/view/NgCqua4VVQjq9ibVWHVWca/adRiTkvKf4AnDsZYyXatz8 World Orphan Drug Congress (Boston) Poster P
Results provide important clinical evidence to support ApolloBio's future regulatory submission in China of VGX-3100, INOVIO's DNA immunotherapy candidateApolloBio's new clinical results further highlight the potential of INOVIO's DNA medicine platform to treat diseases caused by infection with various strains of the human papillomavirus (HPV), eliminating or reducing the need for surgical interventionsPLYMOUTH MEETING, Pa., May 21, 2026 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that its partner for VGX-3100 in
Biologics License Application (BLA) for INO-3107 actively being reviewed under the accelerated approval program by the U.S. Food and Drug Administration (FDA) with a target Prescription Drug User Fee Act (PDUFA) date of October 30, 2026 Commercial readiness plans continue to advance in anticipation of a potential commercial launch for INO-3107 as a treatment for adults with Recurrent Respiratory Papillomatosis (RRP)Clinical trial collaboration and supply agreement announced with Akeso Inc. to evaluate INO-5412 in combination with cadonilimab for the potential treatment of glioblastoma (GBM) in a Dana-Farber Cancer Institute-sponsored trialCurrent cash, cash equivalents, and short-term invest
SC 13G - INOVIO PHARMACEUTICALS, INC. (0001055726) (Subject)
SC 13G/A - INOVIO PHARMACEUTICALS, INC. (0001055726) (Subject)
SC 13G/A - INOVIO PHARMACEUTICALS, INC. (0001055726) (Subject)
LONDON and PHILADELPHIA, July 01, 2025 (GLOBE NEWSWIRE) -- Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs, today announces the appointment of David Liebowitz, M.D., Ph.D. as Chief Medical Officer (CMO) and Yulii Bogatyrenko as an advisor in business development. Dr. Liebowitz will lead the Company's clinical strategy and execution as it continues to advance its pipeline of targeted cancer therapies and Mr. Bogatyrenko will add additional strength to the Group's business development strategy. Dr. Liebowitz is a seasoned hematologist-oncologist and drug development leader with more than 30 years of experience across academia and indust
PLYMOUTH MEETING, Pa., Jan. 9, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today highlighted anticipated milestones for 2025 and key accomplishments from 2024 in advance of upcoming investor meetings. "Based on the progress achieved in 2024, we anticipate 2025 to be a transformational year for INOVIO as we move closer to our goal of becoming a commercial-stage company providing a breakthrough therapy for pati
Mr. Egge brings over 25 years of biopharmaceutical experience building commercial organizations and successfully launching novel therapeutic products INOVIO poised to become a commercial-stage company with plans to submit a Biologics License Application for INO-3107 in second half of 2024 under U.S. Food and Drug Administration's Accelerated Approval Pathway PLYMOUTH MEETING, Pa., July 2, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the appointment of Steven Egge as Chief Commercial Officer. Mr. Egge will le
PLYMOUTH MEETING, Pa., May 1, 2026 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that its first quarter 2026 financial results will be released after the market close on May 13th, 2026. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss the financial results and provide a general business update. The live webcast will be available online at http://ir.i
Biologics License Application (BLA) for INO-3107 accepted for review under the Accelerated Approval Program as a potential treatment for adults with Recurrent Respiratory Papillomatosis (RRP) by the U.S. Food and Drug Administration (FDA); target Prescription Drug User Fee Act (PDUFA) date October 30, 2026 INO-3107 immunological and long-term clinical and safety data published in Nature Communications and The Laryngoscope Advanced promising next-generation DNA medicine technology:Phase 1 proof-of-concept trial of DNA-encoded Monoclonal Antibodies (DMAbs) published in Nature MedicinePromising preclinical data on novel DNA-encoded protein (DPROT) technology presented at the World Federation of
PLYMOUTH MEETING, Pa., March 5, 2026 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancers, and infectious diseases, today announced that its fourth quarter and full year 2025 financial results will be released after the market close on March 12, 2026. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss the financial results and provide a general business update. The live webcast will be available